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Purpose: Matrix metalloproteinases (MMPs) are postulated to be involved in the development of retinal angiogenesis
through the regulation of extracellular matrix. The objective of the present study was to test for a possible association of
five single nucleotide polymorphisms (SNPs) in the MMP-2 gene and two polymorphisms in the MMP-9 gene with
proliferative diabetic retinopathy (PDR) and to determine their plasma levels.
Methods: The study comprised 490 Caucasian participants, who were divided into three groups: diabetics with PDR,
diabetics without PDR, and nondiabetics. Genotypes were detected by polymerase chain reactions followed by restriction
analyses with specific endonucleases and their frequencies determined. Plasma levels of MMP-2 and MMP-9 proteins
were analyzed by ELISA.
Results: Neither MMP-2 SNPs nor MMP-9 SNPs revealed significant association with PDR in single-locus comparisons;
similarly, MMP-2 haplotype frequencies did not differ notably between groups, although the C-allele of the −1306C/T
polymorphism and the C-allele containing haplotype (CGCG) in MMP-2 exhibited marginally significant association with
PDR in males (p<0.05, pcorr=NS). Both MMP-2 and MMP-9 plasma levels showed statistically significant differences
among the studied groups (p<0.001 and p=0.001, respectively) with highest levels in the PDR group. MMP-2 plasma
levels were markedly higher in carriers of either the −1306CC and −1306CT genotypes and (p=0.009) or CGCG haplotype
(p=0.043).
Conclusions: These findings indicate that genotype- and haplotype-specific effects on MMP-2 expression corresponding
with its plasma levels may contribute to the susceptibility to PDR.
Proliferative diabetic retinopathy (PDR) is characterized
by active angiogenesis in the retina and the formation of
fibrovascular  tissue  at  the  vitreoretinal  interface  [1].
Angiogenesis  involves  migration,  proliferation,
differentiation, and adhesion of cells and is influenced by the
surrounding  extracellular  matrix  (ECM).  These  processes
require regulation and local production of angiogenic factors
[2,3] as well as synthesis of ECM components necessary for
the anchorage of migrating endothelial and other cells, such
as retinal pigment epithelium, glial cells, and fibroblasts [4,
5].  Degradation  of  ECM  proteins  is  exerted  by  matrix
metalloproteinases  (MMPs),  whose  activity  is,  in  turn,
regulated by natural inhibitors known as tissue inhibitors of
MMPs [6]. During angiogenesis, MMPs have an important
role in connective tissue remodeling and in the degradation of
basement membrane and surrounding ECM [7,8]. Thus, the
regulation of angiogenesis may be dependent on the intensity
of expression of these enzymes as well as endocrine and
growth  factors.  Any  genetic  polymorphism  in  the  loci
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encoding MMPs and their corresponding plasma levels could
belong to the risk factors participating in PDR development.
MMPs  belong  to  a  family  of  zinc-containing  ECM-
degrading  enzymes  that  share  common  structural  and
functional properties [9]. The important molecules controlling
the formation of new vessels are gelatinase A (MMP-2) and
gelatinase B (MMP-9), which have the ability to cleave type
IV collagen, a major component of the basement membrane.
Some studies reported that both MMPs play an important role
in the regulation of angiogenesis and may be relevant to the
development of the proliferative phase of DR [10-12].
Genetic variability in the regulatory regions of the genes
is one of the significant factors that influence levels of MMPs.
Several polymorphisms have been identified in the promoter
and coding regions of MMP-2 and MMP-9 [13-16]. In this
study, we examined five polymorphisms in MMP-2 (−168G/
T, −735C/T, −790T/G, −1306C/T, and –1575G/A) and two
polymorphisms  in  MMP-9  (−1562C/T  and  R279Q).  We
employed the following selection criteria: frequency of the
minor  allele  ≥5%;  and  previous  evidence  that  sequence
variants in the promoters influence expression as well as levels
of MMPs. Polymorphism –1306C/T of MMP-2 was shown to
be linked to a strikingly lower promoter activity associated
with the T-allele [14]. Similarly, SNP –1562C/T of MMP-9
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1114was  found  to  influence  transcription  in  an  allele-specific
manner, the T-allele having a greater strength than the C-
allelic promoter [17]. We hypothesized that susceptibility to
the development of PDR may be associated with the presence
of particular alleles at the MMPs loci.
The aim of the present study was to employ PDR to find
a possible association of genetic variations in MMP-2 and
MMP-9. Furthermore, we determined MMP-2 and MMP-9
plasma  levels  in  subjects  studied  and  analyzed  mutual
relationships between plasma level of product and genetic
variability within the particular gene.
METHODS
Subjects: The present study enrolled 490 unrelated Caucasian
subjects, 304 of whom had type 2 diabetes mellitus (DM). All
participants were divided into three groups: diabetics with
PDR  (PDR),  diabetics  without  PDR  (non-PDR),  and
nondiabetics  (non-DM).  DM  was  diagnosed  previously
according  to  the  World  Health  Organization  criteria.  All
diabetic participants were on some form of treatment. Mean
known duration of DM was 11.4±0.56 years (mean±SE). The
PDR group consisted of 129 patients (66 men and 63 women),
and  their  average  age  was  62.3±0.72  years  (range  47–79
years).  All  PDR  subjects  regularly  attended  a  specialized
diabetology  unit  of  the  Department  of  Ophthalmology,
University Hospital Brno, Czech Republic. PDR was assessed
by  direct  ophthalmoscopy  through  dilated  pupils  of  PDR
patients and classified as proliferative according to the early
treatment  diabetic  retinopathy  (ETDR)  criteria
[18].Ophthalmologic  examinations  of  PDR  patients  were
performed  several  times  per  year.  The  non-PDR  group
(n=175) was composed of 175 participants (80 men and 95
women) whose average age was 64.3±0.95 years. The non-
DM group had 186 participants (61 men and 125 women) who
had no personal history or clinical signs of diabetes. The
average age of participants in this group was 59.4±0.99 years.
Only the non-DM group (control group) had no evidence of
cardiovascular disease, cancer, or allergy, and they were not
taking any long-term medication. Signed informed consent
was obtained from every participant in each group before their
insertion  in  the  study.  The  present  study  was  conducted
according to the principles of the Declaration of Helsinki and
was approved by the Ethical Committee, Medical Faculty,
Masaryk University, Brno, Czech Republic.
PCR  for  MMP-2  and  MMP-9  single  nucleotide
polymorphisms: Peripheral blood (5 ml) of all investigated
subjects was obtained and mixed with EDTA. Genomic DNA
was  isolated  from  5  ml  EDTA-anticoagulated  peripheral
blood leukocytes by a standard extraction method and used as
a template for PCR. Reactions were performed in a final
volume of 25 µl, containing 50 mM KCl, 10 mM TRIS-HCl
buffer, pH 8.4, 1.5 mM MgCl2, 10 pmol of each primer (Table
1), 200 µM dNTP, 1 µg of genomic DNA in the presence of
0.7 U of Taq polymerase (MBI Fermentas, Glen Burnie, MD).
After the initial denaturation step (95 °C for 5 min), each cycle
(of additional 30 cycles) consisted of a 95 °C denaturation for
30 s, 30 s of annealing, a 72 °C extension for 30 s, and a final
extension lasting 8 min at 72 °C. Polymorphisms (−735C/T,
−790T/G,  −1306C/T,  and  –1575G/A)  were  genotyped  by
PCR and subsequent restriction with specific endonucleases
according  to  methods  described  elsewhere  [15].  Those
polymorphisms were analyzed by the standard PCR method
which  was  mentioned  above.  The  primer  sequences,
annealing temperatures, PCR product and locations for all
methods are given in Table 1. In the case of the −168G/T
polymorphism,  15  μl  aliquots  of  the  PCR  product  were
digested with 3 U of BseDI (MBI Fermentas) for 5 h at 55 °C.
Digestion revealed fragments of 26 bp, 194 bp, and 205 bp for
the wild-type allele and 26 bp and 399 bp for the mutated
allele.
Polymorphisms −1562C/T and R279Q in MMP-9 were
detected using a modified PCR method based on the published
single-strand  conformation  polymorphism  technique  [16].
Aliquots (10 μl) of the −1562C/T PCR product were digested
with 3 U PaeI (MBI Fermentas) for 5 h at 37 °C. Digestion
revealed fragments of 144 and 185 bp for the mutated allele.
The wild type allele C lacked the PaeI restriction site. In the
case of the R279Q polymorphism, 10 μl of PCR product were
digested with 3 U of SmaI (MBI Fermentas) for 5 h at 30 °C.
Digestion revealed fragments of 22 and 73 bp for the wild type
allele. The mutated allele Q lacked the SmaI restriction site.
Determination  of  metalloproteinase-2  and
metalloproteinase-9  plasma  levels:  For  determination  of
plasma  levels  of  MMPs  the  human  MMP-2  and  MMP-9
ELISA  Kits  (RayBiotech,  Inc.,  Norcross,  GA)  were  used
according to the manufacturer's instructions. The minimum
detectable dose was less than 80 pg/ml of MMP-2 and 10 pg/
ml of MMP-9, respectively.
Statistical analysis: Differences in genotype distribution and
consistency with Hardy–Weinberg equilibrium were tested by
chi-square test. Differences in allele frequencies of SNPs were
tested by two-tailed Fisher exact test. PHASE v. 2.0 [19]
software was used to resolve a sample of phase-unknown
multilocus genotypes and to estimate population haplotype
frequencies by the Bayesian-based algorithm. Comparison of
the  estimated  haplotype  frequencies  was  performed  as
omnibus testing of differences in haplotype frequency profiles
between  the  two  groups  (statistical  significance  assessed
empirically via permutation testing). In addition, haplotype-
specific effects were analyzed using inferred haplotype pairs
by computing chi-square statistics.
Normally distributed metric parameters (Kolmogorov–
Smirnov test) were presented as mean ± standard error of the
mean (SE), others as median (range). Mann–Whitney U-test,
Kruskal–Wallis ANOVA and Spearman rank correlation tests
were  used  where  appropriate.  Values  of  p<0.05  were
considered  to  be  statistically  significant.  Bonferroni
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1115correction (pcorr) was applied in case of multiple comparisons
modifying  the  significant  p-value  threshold  according  to
number of comparisons. Statistical analyses were performed
using program package Statistica for Windows (StatSoft Inc.,
Tulsa, OK).
RESULTS
Genetic  polymorphisms  of  metalloproteinase-2  and
metalloproteinase-9  genes  and  proliferative  diabetic
retinopathy: Genotype frequencies of all SNPs (−168G/T,
−735C/T, −790T/G, −1306C/T, 
–1575G/A, −1562C/T, and R279Q) in the individual groups
are shown in Table 2. Genotype distribution of any of the
seven  polymorphism  studied  did  not  differ  from  Hardy–
Weinberg  equilibrium  in  any  group  (p>0.05).  Similarly,
genotype frequencies of any polymorphisms did not differ
significantly  between  groups  in  pair-wise  comparison
(p>0.05).  Comparison  of  allele  frequencies  showed
statistically significant difference in allele frequencies of the
-1306C/T polymorphism between the PDR versus non-DM
groups (p=0.024), however, after the correction for multiple
comparison  the  difference  did  not  remained  significant
(pcorr>0.05). The calculated odds ratio (OR) for the CC and
CT  genotypes  was  1.41  (95%  confidence  interval  (CI):
0.52±3.87).
Testing for association carried separately for males and
females  revealed  statistically  significant  gender-specific
association of the two MMP-2 polymorphisms (−168G/T and
−1306C/T), in particular, differences in genotype as well as
in allele frequencies between the PDR and non-DM groups
(Table 3). In female subjects, the significant differences in
genotype  distribution  (p=0.040)  and  allele  frequency
(p=0.016) were found for −168G/T polymorphism. Female
subjects carrying the −168T allele had a 2.45 fold higher risk
of developing PDR (OR=2.45, 95% CI: 1.16–5.20) than those
not carrying this allele. On the other hand, the statistically
significant  difference  in  genotype  distribution  (allele
frequency) of −1306C/T polymorphism was found in male
subjects between the same groups (p=0.039 and p=0.024). The
calculated OR for patients carrying the −1306C allele was
1.88 (95% CI: 1.05–3.40). However, after taking the number
of  comparisons  into  account,  we  found  none  of  the
significances remained statistically significant (pcorr>0.05).
Haplotype analysis was performed to compare the sum
effect  of  genetic  variability  of  the  four  polymorphisms
(−1306C/T, −790T/G, −735C/T and −168G/T) in MMP-2.
The −1575G/A polymorphism was omitted due to the strong
linkage  disequilibrium  between  −1306C/T  and  −1575G/A
polymorphisms. Haplotypes were constructed from genotype
data of all subjects computationally using PHASE software
with the assumption of mutual independence of haplotypes.
No statistically significant difference was found in haplotype
frequencies between the groups studied (omnibus p>0.05;
10,000 permutations). Analyses performed separately for men
and women revealed a statistically significant difference in
males  (omnibus  p=0.042;  10,000  permutations);  while  no
significant  difference  was  observed  in  females  (omnibus
p=0.738, 10 000 permutations). The pair-wise comparison of
groups in males showed significant differences in haplotype
frequencies between PDR versus non-PDR groups (p=0.031).
To  analyze  haplotype-specific  effects  on  the  trait  (i.e.,
presence  of  PDR),  we  asigned  pairs  of  haplotypes  to
individuals. Subsequently, numbers of individuals with this
particular haplotype were counted. Table 4 shows the absolute
numbers of haplotypes in particular groups that were inferred
retrospectively with probability more than 90%. Carriers of
haplotypes with frequencies <1% in all three groups were
pooled together as “rare.” Separate one-degree of freedom
TABLE 1. PCR REACTION CONDITIONS
Gene SNP Primer sequence (sense/antisense) Ta (°C) Product (bp)
MMP-2
−168G/T 5′-CTGACCATTCCTTCCCGTTC-3′ 51 425
5′-CGCCTGAGGAAGTCTGGAT-3′
−735C/T 5′-ATAGGGTAAACCTCCCCACATT-3′ 59 300
5′-GGTAAAATGAGGCTGAGACCTG-3′
−790T/G 5′-GGGTCTTTGTGACCTCGATC-3′ 56 118
5′-GGTAAAATGAGGCTGAGACCTG-3′
−1306C/T 5′-CTTCCTAGGCTGGTCCTTACTGA-3′ 49 193
5′-CTGAGACCTGAAGAGCTAAAGAGCT-3′
−1575G/A 5′-ACTGACTCTGGAAAGTCAGAGCAG-3′ 60 269
5′-GGCACAGGGTGAGGGGATGG-3′
MMP-9
−1562C/T 5′-ATGCTCATGCCCGTAATCCT-3′ 65 329
5′-GGGGTAGTATCACTCTGTCACC-3′
R279Q 5′-CTCGCCCCAGGACTCTACAC-3′ 60 95
5′-GTGCAGGCGGAGTAGGATT-3′
The table summarizes the primer sequences, annealing temperatures, and PCR product lengths.
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1116TABLE 2. GENOTYPE DISTRIBUTIONS OF MMP-2 AND MMP-9 POLYMORPHISMS
MMP-2
−168G/T
GG (%) GT (%) TT (%) (1) vs. (2) (2) vs. (3) (1) vs. (3)
PDR (n=128) (1) 106 (83) 19 (15) 3 (2)
non-PDR (n=175) (2) 151 (86) 23 (13) 1 (1)
NS
NS
NS
NS
NS
NS
non-DM (n=186) (3) 157 (84) 29 (16) 0 (0)
MMP-2
−735C/T
CC (%) CT (%) TT (%) (1) vs. (2) (2) vs. (3) (1) vs. (3)
PDR (n=128) (1) 95 (74) 32 (25) 2 (1)
non-PDR (n=175) (2) 136 (78) 38 (22) 1 (0)
NS
NS
NS
NS
NS
NS
non-DM (n=186) (3) 142 (76) 40 (22) 4 (2)
MMP-2
−790T/G
TT (%) TG (%) GG (%) (1) vs. (2) (2) vs. (3) (1) vs. (3)
PDR (n=128) (1) 74 (57) 46 (36) 9 (7)
non-PDR (n=175) (2) 92 (54) 66 (38) 14 (8)
NS
NS
NS
NS
NS
NS
non-DM (n=186) (3) 90 (48) 85 (46) 11 (6)
MMP-2
−1306C/T
CC (%) CT (%) TT (%) (1) vs. (2) (2) vs. (3) (1) vs. (3)
PDR (n=128) (1) 79 (61) 44 (34) 6 (5)
non-PDR (n=175) (2) 94 (54) 66 (38) 15 (9)
NS
NS
NS
NS
NS
(p=0.024)
non-DM (n=186) (3) 90 (48) 84 (45) 12 (7)
MMP-2
−1575G/A
GG (%) GA (%) AA (%) (1) vs. (2) (2) vs. (3) (1) vs. (3)
PDR (n=128) (1) 73 (57) 49 (38) 7 (5)
non-PDR (n=175) (2) 94 (54) 66 (38) 15 (9)
NS
NS
NS
NS
NS
NS
non-DM (n=186) (3) 90 (48) 84 (45) 12 (7)
MMP-9
−1562C/T
CC (%) CT (%) TT (%) (1) vs. (2) (2) vs. (3) (1) vs. (3)
PDR (n=128) (1) 94 (73) 32 (25) 3 (2)
non-PDR (n=175) (2) 126 (72) 47 (27) 2 (1)
NS
NS
NS
NS
NS
NS
non-DM (n=186) (3) 134 (72) 49 (26) 3 (2)
MMP-9
R279Q
RR (%) RQ (%) QQ (%) (1) vs. (2) (2) vs. (3) (1) vs. (3)
PDR (n=128) (1) 44 (34) 69 (54) 16 (12)
non-PDR (n=175) (2) 73 (42) 83 (47) 19 (11)
NS
NS
NS
NS
NS
NS
non-DM (n=186) (3) 70 (38) 86 (46) 30 (16)
There were no significant differences between the groups when comparing genotype distributions (p>0.05). The statistically
significant difference was found in allele frequencies of −1306C/T polymorphism between the proliferative diabetic retinopathy
(PDR versus non-diabetes mellitus (DM) groups (p=0.024; pcorr>0.05). Genotype distribution of any polymorphism did not differ
from Hardy-Weinberg equilibrium in any group (p>0.05). The p-values of allele frequencies (two-tail Fisher exact test) are
given in parentheses.
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1117tests were conducted for a series of 2×2 contingency tables
testing the frequency of each specific haplotype versus all
others between particular groups (PDR versus non-PDR and
PDR versus non-DM). Two specific haplotypes, - CGCG
(OR=7.57, i.e., risk haplotype) and TGCG (OR=0.56, i.e.,
protective haplotype), exhibited significant associations with
PDR in male patients (p=0.030 and p=0.041, respectively),
after  the  correction  for  multiple  tests,  however,  the
significances did not remained significant (pcorr>0.05).
Plasma  levels  of  metalloproteinase-2  and
metalloproteinase-9 versus genetic variation: MMP-9 plasma
levels were 12.3 ng/ml (8.0–16.7 ng/ml) in the PDR group,
11.3 ng/ml (7.9–13.1 ng/ml) in the non-PDR group and 10.3
ng/ml  (2.0–13.7  ng/ml)  in  the  non-DM  group  (p=0.001,
Kruskal–Wallis ANOVA). Using the Mann–Whitney U test,
we observed significant differences in the plasma levels of
MMP-9 between the PDR or non-PDR groups and the non-
DM group (p<0.001 and p=0.006, respectively), while we
observed no notable difference between the PDR and non-
PDR groups (p=0.079). No significant differences were found
between MMP-9 genetic variations (groups defined according
to the −1562C/T or R279Q polymorphism genotypes), and
plasma levels of the MMP-9 in the whole sample or within
each gender and study group separately (p>0.05).
MMP-2 plasma levels were 401.5 ng/ml (142.4–633.4
ng/ml) in the PDR group, 277.9 ng/ml (118.0–473.5 ng/ml) in
the non-PDR group, and 260.8 ng/ml (44.8–428.2 ng/ml) in
the non-DM group (p<0.001, Kruskal–Wallis ANOVA). The
Mann–Whitney  U  test  revealed  statistically  notable
differences in MMP-2 between the PDR and non-PDR or non-
DM  groups  (p=0.001  and  p<0.001,  respectively).  A
comparison of plasma levels of MMP-2 corresponding to
TABLE 3. COMPARISONS OF GENOTYPE DISTRIBUTIONS OF THE TWO MMP-2 POLYMORPHISMS IN MALE AND FEMALE SUBJECTS.
Males
MMP-2
−168G/T
GG (%) GT (%) TT (%) (1) vs. (2) (2) vs. (3) (1) vs. (3)
PDR (n=65) (1) 57 (88) 7 (11) 1 (1)
non-PDR (n=80) (2) 69 (86) 11 (14) 0 (0)
NS
NS
NS
NS
NS
NS
non-DM (n=61) (3) 46 (75) 15 (25) 0 (0)
MMP-2
−1306C/T
CC (%) CT (%) TT (%) (1) vs. (2) (2) vs. (3) (1) vs. (3)
PDR (n=66) (1) 42 (64) 24 (36) 0 (0)
non-PDR (n=80) (2) 43 (54) 32 (40) 5 (6)
NS
NS
NS
NS
p=0.039
(p=0.024)
non-DM (n=61) (3) 29 (47) 28 (46) 4 (7)
Females
MMP-2
−168G/T
GG (%) GT (%) TT (%) (1) vs. (2) (2) vs. (3) (1) vs. (3)
PDR (n=63) (1) 49 (78) 12 (19) 2 (3)
non-PDR (n=95) (2) 82 (86) 12 (13) 1 (1)
NS
NS
NS
NS
p=0.040
(p=0.016)
non-DM (n=125) (3) 111 (89) 14 (11) 0 (0)
MMP-2
−1306C/T
CC (%) CT (%) TT (%) (1) vs. (2) (2) vs. (3) (1) vs. (3)
PDR (n=63) (1) 37 (59) 20 (32) 6 (9)
non-PDR (n=95) (2) 51 (54) 34 (36) 10 (10)
NS
NS
NS
NS
NS
NS
non-DM (n=125) (3) 61 (49) 56 (45) 8 (6)
The table shows the statistical significance of differences in allele frequencies (the p-values of two-tail Fisher exact test are
given in parentheses) and genotype distribution (χ2 test) between the studied groups for the two sexes separately. In female
subjects, the significant difference was found in allele frequency of the −168G/T polymorphism between the proliferative
diabetic retinopathy (PDR) and non-diabetes mellitus (DM) groups (p=0.016, odds ratio (OR)=2.45, 95% CI: 1.16-5.20). In
male subjects the −1306C/T polymorphism exhibited statistically significant difference in allele frequency between the same
groups (p=0.024, OR=1.88 (95% CI: 1.05-3.40). However, after the correction for multiple comparisons differences were no
longer significant (pcorr>0.05).
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1118particular genotypes of MMP-2 SNPs showed a statistically
significant  difference  for  the  −1306C/T  variant  (p=0.011,
Kruskal–Wallis  ANOVA).  The  plasma  levels  were
significantly higher in the CC and CT genotypes, compared
to TT in diabetic patients (p=0.009, Mann–Whitney U test).
No  gender-specific  differences  were  ascertained  for  the
−1306C/T  variant  and  MMP-2;  this  was  mostly  due  to
incomparably low numbers of TT genotypes after splitting the
whole group into two genders.
The comparison of plasma levels of MMP-2 among the
haplotype  groups–i.e.,  risk  (CGCG)  versus  the  protective
(TGCG)  versus  all  others–revealed  the  highest  MMP-2
plasma levels were in the risk haplotype group (p=0.043,
Kruskal–Wallis ANOVA). The median (range) of MMP-2
was  388.1  ng/ml  (186.4–633.4  ng/ml)  in  the  PDR-risk
haplotype, 269.2 ng/ml (185.3 – 473.5 ng/ml) in the protective
haplotype, and 259.5 ng/ml (44.8–425.8 ng/ml) in others,
respectively. As with the previous situation, gender-specific
differences were not ascertained due to low numbers of risk
haplotypes after dividing the study population into women
and men.
Furthermore, because advanced age and DM duration are
risk factors for PDR, we analyzed the correlation between the
plasma levels of MMP-2 and MMP-9 and the aforementioned
parameters.  A  statistically  significant  Spearman  rank
correlation was found between plasma level of MMP-2 and
DM duration (Rs=0.376; p=0.005) while no other correlation
was ascertained.
DISCUSSION
So far, no association study of genetic variability in MMP-2
and  MMP-9  and  PDR  has  been  published.  Retinal
angiogenesis is a hallmark of PDR, involving the production
of angiogenic factors as well as synthesis of ECM proteins.
Both MMP-2 and MMP-9 are interesting candidate genes for
PDR because of their role in connective tissue remodeling and
in  regulation  of  extracellular  matrix  during  angiogenesis
[20].
Analysis of individual polymorphisms showed that their
frequencies in Czech Caucasian subjects are similar to those
described previously [15,21], however, none of individual
polymorphism was associated with PDR in this study. Allele
frequencies of the −168G/T and −1306C/T polymorphisms
differed marginally in female and male study participants
between  the  PDR  and  control  groups;  however,  the
interpretation of suggestive gender-specific differences is not
straightforward. One possible explanation might be a different
modulatory  effect  of  sex  hormones  on  cytokine-regulated
gene expression of MMP-2 or regulation of MMP-2 plasma
levels [22,23]. While single-locus association studies have
prevailed  in  the  past,  haplotype-based  association  studies
offer more robust approach to the analysis of complex traits
since  these  studies  consider  the  whole  genetic  variability
within the particular locus as a unit. Previously we showed
that  TGF-β1  haplotypes  might  play  a  role  in  PDR
susceptibility [24]. Furthermore, specific haplotypes based on
SNPs  in  the  promoter  region  of  the  MMP-2  gene  were
associated  with  coronary  artery  disease  [15].  The  present
study identified two specific haplotypes, CGCG (risk) and
TGCG (protective), which were marginally associated with
PDR in male patients. This is in agreement with the results of
single-locus association since the C allele of the −1306C/T
variant significantly associated with PDR in male subjects
defines the two haplotypes.
Several previous studies quantified levels of MMP-2 and
MMP-9 proteins in PDR subjects [25-27]. Data were obtained
by  various  methods  (zymography,  immunoblot,  and
immunohistochemistry),  and  the  results  showed  increased
concentrations of MMP-2 and MMP-9 in patients with PDR
[28,29]. Using ELISA, we confirmed that PDR is associated
with the highest plasma levels of both MMP-2 and MMP-9
compared to non-DM as well as non-PDR groups. Effects of
TABLE 4. HAPLOTYPES DERIVED FROM MMP-2 POLYMORPHISMS IN MALE PATIENTS
Haplotype PDR (%) non-PDR (%)
χ2
(p-value)
OR (95% CI) non-DM (%)
χ2
(p-value)
OR (95% CI)
CTCG 73 (55) 83 (52) NS - 53 (43) NS -
TGCG 23 (17) 44 (28) 0.041 0.56 (0.32-0.98) 34 (28) 0.046 0.55 (0.30-0.99)
CTTG 21 (16) 21 (13) NS - 17 (14) NS -
CTCT 9 (7) 11 (7) NS - 15 (12) NS -
CGCG 6 (5) 1 (1) 0.030 7.57 (0.89-63.71)* 1 (1) NS -
Rare 0 (0) 0 (0) NS - 2 (2) NS -
PDR vs. non-PDR 0.031**
PDR vs. non-
DM
0.068**
MMP-2 haplotypes inferred from the four single nucleotide polymorphisms (SNPs; ordered from the 5′ to 3′as follows: −1306C/
T, −790T/G, −735C/T, and −168G/T) in males. Haplotypes with frequencies less than 1% in both groups were pooled together
as “rare”. χ2 (p-value) was derived from single 2x2 contingency tables testing the frequency of each specific haplotype vs. all
others between particular groups (proliferative diabetic retinopathy [PDR] versus non-PDR and PDR versus non-diabetes
mellitus [DM]). The double asterisk represents omnibus p-value was assessed empirically by permutation testing (PHASE
output, 10 000 permutations). The asterisk means an odds ratio>1.5 was significantly associated with PDR.
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were also described by Price and Zhang [14,17]. The transition
C→T  of  the  −1306C/T  polymorphism  displayed  a  lower
promoter  activity  for  the  T  allele  [17].  Furthermore,  the
−1575G  allele  increased  transcription  activity  and  had  an
independent additive effect with the −1306C allele [30]. Our
results support an importance of the −1306C/T polymorphism
as a factor determining the intermediate phenotype, since the
risk CC/CT genotypes and risk haplotype containing the C
allele exhibited significantly highest plasma level of MMP-2
protein. Unfortunately, we could not pursue the possible effect
of male gender-specific association in the study of its effect
on MMP-2 levels since the numbers were too low in some
groups of genotypes or haplotypes to allow for an adequate
comparison. Nevertheless, the topic is intriguing enough to
warrant further study on a larger group.
In conclusion, we demonstrated plasma levels of MMP-2
are notably higher in patients with PDR, and they exhibit
significant  −1306C/T  genotype-  and  haplotype-specific
differences with higher levels in the CC/CT genotypes and
CGCG haplotype. Although we have not been able to prove
statistically  significant  association  of  those  MMP-2  gene
variants  with  PDR,  both  suggestive  risk  genotypes  and
haplotype  are  overrepresented  in  the  PDR  group  which
explains the observed difference in the MMP-2 plasma levels
between  patient  groups.  The  gender-specific  effects  on
MMP-2 regulation require further study.
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